158 related articles for article (PubMed ID: 38062123)
1. Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
Mattano LA; Devidas M; Loh ML; Raetz EA; Chen Z; Winick NJ; Hunger SP; Carroll WL; Larsen EC
Leukemia; 2024 Feb; 38(2):258-265. PubMed ID: 38062123
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.
Larsen EC; Devidas M; Chen S; Salzer WL; Raetz EA; Loh ML; Mattano LA; Cole C; Eicher A; Haugan M; Sorenson M; Heerema NA; Carroll AA; Gastier-Foster JM; Borowitz MJ; Wood BL; Willman CL; Winick NJ; Hunger SP; Carroll WL
J Clin Oncol; 2016 Jul; 34(20):2380-8. PubMed ID: 27114587
[TBL] [Abstract][Full Text] [Related]
3. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
4. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.
DiNofia AM; Seif AE; Devidas M; Li Y; Hall M; Huang YV; Cahen V; Hunger SP; Winick NJ; Carroll WL; Fisher BT; Larsen EC; Aplenc R
Cancer Med; 2018 Jan; 7(1):3-12. PubMed ID: 29274118
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
[TBL] [Abstract][Full Text] [Related]
6. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
Mattano LA; Sather HN; Trigg ME; Nachman JB
J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
Burke MJ; Devidas M; Chen Z; Salzer WL; Raetz EA; Rabin KR; Heerema NA; Carroll AJ; Gastier-Foster JM; Borowitz MJ; Wood BL; Winick NJ; Carroll WL; Hunger SP; Loh ML; Larsen EC
Leukemia; 2022 Mar; 36(3):648-655. PubMed ID: 34725453
[TBL] [Abstract][Full Text] [Related]
9. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
[TBL] [Abstract][Full Text] [Related]
10. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
[TBL] [Abstract][Full Text] [Related]
11. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
Salzer WL; Burke MJ; Devidas M; Dai Y; Hardy KK; Kairalla JA; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
J Clin Oncol; 2020 Aug; 38(23):2628-2638. PubMed ID: 32496902
[TBL] [Abstract][Full Text] [Related]
12. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
[TBL] [Abstract][Full Text] [Related]
14. Bony morbidity in children treated for acute lymphoblastic leukemia.
Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
[TBL] [Abstract][Full Text] [Related]
15. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
16. Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study.
Bassal M; Silva M; Patel S; Gibson PJ; Breakey VR; Athale U; Zabih V; Li Q; Pechlivanoglou P; Pole JD; Mittmann N; Sutradhar R; Gupta S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29141. PubMed ID: 34003566
[TBL] [Abstract][Full Text] [Related]
17. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
[TBL] [Abstract][Full Text] [Related]
18. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis in pediatric patients with acute lymphoblastic leukemia.
Murphy RG; Greenberg ML
Cancer; 1990 Apr; 65(8):1717-21. PubMed ID: 2317754
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
